Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 11INDUSTRY 4NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Leukoplakia, Oral 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Cyclophosphamide 385Specimen Handling 371Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Interventional × Rosiglitazone × Clear all
NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT00369174 2013-02-13

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

National Cancer Institute (NCI)

Phase 2 Completed
25 enrolled
Head & Neck

Leukoplakia, Oral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡